None
Conditions
Interventions
Group S:Sufentanil 100 µg diluted to 100 mL, loading dose 5 µg, background infusion 2 mL/h, bolus 0.5 µg, lock-out 15 min.
Group T:Tegileridine 10 mg diluted to 100 mL, loading dose 1.5–2.0 mg, background infusion 2 mL/h, bolus 0.05 mg, lock-out 15 min.
Sponsors
Shaoxing People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ASA class I–III, aged 18–80 years, scheduled for major abdominal surgery (e.g., laparoscopic radical gastrectomy, gastric sleeve surgery colorectal resection, hepatectomy, radical prostatectomy), BMI >30 kg/m² or pre-operatively diagnosed obstructive sleep apnea, receiving intravenous patient-controlled analgesia (PCIA), mentally competent, able to understand VAS and operate PCIA pump, expected surgical time >=120 min.
Exclusion criteria
Exclusion criteria: Difficult airway, pre-operative percutaneous oxygen saturation (SpO2) <90%, allergy to study drugs (sufentanil, tegileridine, etc.), use of medications that may affect study results within 24 h before surgery (e.g., opioids, sedatives), severe dysfunction of vital organs (heart, lung, liver, kidney), serious respiratory diseases other than OSA, history of drug dependence or substance abuse, refusal to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of impaired respiratory function within 0–24 hours postoperatively; | — |
Countries
China
Contacts
Public ContactZongming Jiang
Shaoxing People's Hospital
Outcome results
None listed